Kristiaan Nackaerts

Publications (4)12.76 Total impact

• Article: Bisphosphonates: prevention of bone metastases in lung cancer.

  Lynn Decoster, Filippo de Marinis, Kostas Syrigos, Vera Hirsh, Kristiaan Nackaerts
  [show abstract] [hide abstract]
  ABSTRACT: In patients with lung cancer, bone is one of the most frequent sites of distant spread, with approximately 30% of patients developing skeletal metastases. About half of these patients will experience a skeletal-related event, the occurrence of which not only affects quality of life, but is also associated with poor prognosis. Bisphosphonates are currently the mainstay for treating bone metastases in patients with lung cancer, with proven beneficial effects on prevention and delay of skeletal complications. Their role in preventing the development of skeletal metastases, their anti-tumoral properties and their effect on survival remain to be elucidated. Other bone-targeted therapies are being investigated in phase II and III clinical trials and might expand the therapeutic arsenal in the near future.
  Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 01/2012; 192:93-108.
• Article: Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel.

  Filippo De Marinis, Wilfried Eberhardt, Peter G Harper, Bartomeu Massuti Sureda, Kristiaan Nackaerts, Jens Benn Soerensen, Kostas Syrigos, Jean Trédaniel
  [show abstract] [hide abstract]
  ABSTRACT: Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases in a variety of solid tumors, including lung cancer. The purpose of this article is to review the current evidence for the use of BPs in lung cancer and to provide specific European recommendations to support the clinical practice of using BPs to treat patients with lung cancer with bone metastases. An expert panel of European clinical oncologists and lung cancer specialists convened for two face-to-face meetings designed to review available evidence on the efficacy of BPs in lung cancer and to develop recommendations based on published literature and clinical practice experiences. The panel recommends screening patients with lung cancer for bone metastases at the initial staging of disease to assess symptomatic bone metastases and screen for asymptomatic bone metastases and to allow accurate monitoring of bone disease progression and initiate bone-specific therapy. Bone assessment should be based on positron emission tomography (if available) or bone scan. BPs should be added to the treatment of patients with lung cancer (with non-small cell lung cancer or small cell lung cancer) who develop bone metastases. In such patients, BPs must be considered part of metastatic lung cancer treatment to prevent and delay the occurrence of further bone metastases and skeletal-related events and to relieve pain where present. BP treatment should continue for as long as it is practically feasible in the absence of any significant adverse effects.
  Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 09/2009; 4(10):1280-8. · 4.55 Impact Factor
• Article: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

  Armando Santoro, Mary E O'Brien, Rolf A Stahel, Kristiaan Nackaerts, Paul Baas, Meinolf Karthaus, Wilfried Eberhardt, Luis Paz-Ares, Stein Sundstrom, Yushan Liu, Veronique Ripoche, Johannes Blatter, Carla M Visseren-Grul, Christian Manegold
  [show abstract] [hide abstract]
  ABSTRACT: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP. Patients with histologically confirmed MPM, not amenable to curative surgery, received pemetrexed 500 mg/m in combination with either cisplatin 75 mg/m or carboplatin AUC 5, once every 21 days with standard premedication. Efficacy data were recorded at the end of study participation. A total of 1704 chemonaïve patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available. The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months). The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group. This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
  Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 08/2008; 3(7):756-63. · 4.55 Impact Factor
• Article: Open-label study of pemetrexed alone or in combination with a platinum in chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP): C5-01

  Christian Manegold, Armando Santoro, Mary E.r. O'Brien, Rolf A. Stahel, Kristiaan Nackaerts, Paul Bass, Luis Paz-Ares, Stein Sundstrom, Carla Visseren-Grul, Johannes Blatter
  Journal of Thoracic Oncology 07/2007; 2(8):S371. · 3.66 Impact Factor